Canaccord Genuity initiates coverage on Relay Therapeutics with Buy rating
Canaccord Genuity analyst John Newman has initiated coverage on Relay Therapeutics with a Buy rating and a price target of $29.
*this image is generated using AI for illustrative purposes only.
Canaccord Genuity analyst John Newman has initiated coverage on Relay Therapeutics with a Buy rating and a price target of $29. The rating reflects a positive outlook on the company's performance.
Coverage Details
The initiation provides a new investment perspective on Relay Therapeutics, which trades on the NASDAQ under the ticker symbol RLAY. The price target of $29 indicates the firm's valuation expectation for the stock.
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $29 |
| Analyst | John Newman |
| Exchange | NASDAQ |
| Ticker Symbol | RLAY |
What upcoming clinical milestones could drive Relay Therapeutics' stock toward the $29 price target?
How does Relay Therapeutics' current valuation compare to its peers in the biotech sector?
What competitive advantages does Relay Therapeutics have that justify the Buy rating?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
